Ms. Colaizzi discusses the decreased funding for cancer trials and the impact this will have on the overall disease states and outcomes for cancer patients.
Decrease In Cancer Funding Nationwide: Impacts on Patients
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Ms. Colaizzi discusses the decreased funding for cancer trials and the impact this will have on the overall disease states and outcomes for cancer patients.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
FCS and SHTG: Are We Meeting the Need?
0.25 credits
<p>FCS and SHTG: Are We Meeting the Need?</p>
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
CME/CE
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
0.50 credits
<p>IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue</p>
CME/CE
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
0.25 credits
<p>IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy</p>
CME/CE Broadcast Replay
Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference
1.00 credits
<p>Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference</p>
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 credits
<p>Level Up Your Skills: Tailoring Management of HF</p>
Cardiology
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
<p><span data-teams="true">Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial</span> </p>
CME/CE
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
<p>FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?